Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01429298 · ClinicalTrials.gov registry record · Phase 4
Comparing Intravenous Hydromorphone to Usual Care
A Phase 4 study, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 350
- Enrollment target
NCT01429298: Completed Phase 4 study, sponsored by Montefiore Medical Center.
NCT01429298 is a Phase 4 study that has completed, run by Montefiore Medical Center. The registered enrollment target is 350 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01429298, a Phase 4 study, has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 350 participants
- Enrollment target
Study Summary
In this randomized controlled trial, 2 mg intravenous (IV) hydromorphone will be more efficacious than usual care (usual care is analgesic management according to the judgment of the attending physician caring for that patient) in emergency department (ED) patients aged 21-64 years. The primary efficacy outcomes are the proportion of patients in each arm who choose to forgo additional pain medication in 30 minutes of entry into the study and the change in numerical rating scale (NRS) pain scores from baseline to 30 minutes post baseline.
Primary Outcome
Amount of patients who choose to forgo additional pain medication at 30 minutes post-baseline when asked the question, "Do you want more pain medication?"
Interventions
- DRUG Hydromorphone
- DRUG Usual care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2010-03 |
| Est. Completion | 2010-11 |
| Phase | Phase 4 |
What the finished NCT01429298 record still lists
NCT01429298 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 2 interventions - of which Hydromorphone is the first listed.
NCT01429298 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01429298 about?
NCT01429298 is a clinical study titled "Comparing Intravenous Hydromorphone to Usual Care". In this randomized controlled trial, 2 mg intravenous (IV) hydromorphone will be more efficacious than usual care (usual care is analgesic management according to the judgment of the attending physician caring for that patient) in emergency department (ED) patients aged 21-64 years. The primary effi...
What is the current status of trial NCT01429298?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 350 participants. The study started on 2010-03. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01429298?
The interventions under investigation include: Hydromorphone (DRUG), Usual care (DRUG).
Who is sponsoring clinical trial NCT01429298?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01429298's enrollment target sits among peer trials
350 231st of 2000 higher than 1,761 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia